A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Trial · NCT01377922
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Placebo | Baseline | 5.6 | Standard Deviation 3.99 | QMG Score |
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Amifampridine Phosphate | Baseline | 6.4 | Standard Deviation 3.22 | QMG Score |
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Placebo | Day 14 | 7.9 | Standard Deviation 2.85 | QMG Score |
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Amifampridine Phosphate | Day 14 | 6.7 | Standard Deviation 4.09 | QMG Score |
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Placebo | Change from Baseline | 2.2 | Standard Deviation 2.93 | QMG Score |
| Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days | Amifampridine Phosphate | Change from Baseline | 0.3 | Standard Deviation 2.60 | QMG Score |
| Change in SGI Score | Placebo | Baseline | 5.9 | Standard Deviation 1.22 | SGI score |
| Change in SGI Score | Amifampridine Phosphate | Baseline | 5.6 | Standard Deviation 1.26 | SGI score |
| Change in SGI Score | Placebo | Day 14 | 3.2 | Standard Deviation 1.7 | SGI score |
| Change in SGI Score | Amifampridine Phosphate | Day 14 | 4.9 | Standard Deviation 1.57 | SGI score |
| Change in SGI Score | Placebo | Change from Baseline | -2.7 | Standard Deviation 2.29 | SGI score |
| Change in SGI Score | Amifampridine Phosphate | Change from Baseline | -0.7 | Standard Deviation 1.82 | SGI score |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Placebo | Baseline | 255 | Standard Deviation 111 | feet/minute |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Amifampridine Phosphate | Baseline | 254 | Standard Deviation 126 | feet/minute |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Placebo | Day 14 | 244 | Standard Deviation 116 | feet/minute |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Amifampridine Phosphate | Day 14 | 253 | Standard Deviation 126 | feet/minute |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Placebo | Change from Baseline | -10.4 | Standard Deviation 53.1 | feet/minute |
| Change From Baseline Timed 25 Foot Walking Test (T25FW) at 14 Days | Amifampridine Phosphate | Change from Baseline | -1.46 | Standard Deviation 52.5 | feet/minute |
| Change in CGI-I Score | Placebo | Baseline | 2.5 | Standard Deviation 0.98 | CGI-I score |
| Change in CGI-I Score | Amifampridine Phosphate | Baseline | 2.6 | Standard Deviation 0.63 | CGI-I score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01377922/results